Price Chart

Executive Summary

The Fourth Circuit affirmed a preliminary injunction in favor of Gilead Sciences, blocking the importation and sale of foreign-market Gilead-branded drugs (including Biktarvy) by alternative funding programs and their facilitators. The court held that the imported drugs are not 'genuine' under the Lanham Act due to material differences in labeling, warnings, and quality control, and that Gilead is likely to succeed on its direct and contributory trademark infringement claims. This ruling protects Gilead's U.S. pricing power and brand integrity by shutting down a gray-market importation channel that threatened to undercut domestic revenue on key HIV drugs.

Court Ruling Details

Key Facts

• The Fourth Circuit affirmed a preliminary injunction barring the importation, advertising, and sale of foreign-market Gilead-branded medications in the U.S.
• The court found that imported Gilead drugs (e.g., Turkish Biktarvy) are not 'genuine' under the Lanham Act due to material differences in labeling, warnings, and quality-control systems.
• The ruling applies to direct infringers (Rx Valet, Advanced Pharmacy, Affordable Rx, Gregory Santulli) and contributory infringers (Meritain Health, ProAct).
• Gilead is likely to succeed on the merits of its trademark claims, and the injunction protects against irreparable harm to Gilead's goodwill and reputation.
• The case originated from a Maryland patient receiving Turkish Biktarvy, leading to discovery of a broader scheme involving hundreds of bottles of imported Gilead medications.

Financial Impact

Protects U.S. revenue from gray-market erosion on key HIV drugs like Biktarvy; no specific dollar amount stated in the ruling.

Risk Factors

• Appellants could seek en banc review or petition the Supreme Court for certiorari, though the opinion is published and unanimous.
• The FDA declined to take enforcement action, leaving the door open for legislative or regulatory changes that could legalize or restrict such importation schemes.
• The injunction is preliminary; a full trial on the merits could yield a different outcome, though the appellate court's strong language suggests Gilead is well-positioned.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 4 court opinions from CourtListener.

US Market Status